SGMT

Sagimet Biosciences Inc. Series A Common Stock (SGMT) | Rumor.io

Sagimet Biosciences

SGMT

Attention (50-day avg)0%

Attention rank (50-day avg)#1,978

Bullish sentiment (50-day avg)70%

Price to earnings ratio-6.29

Market capitalization617.9M

Earnings per share-1.26

Dividend yield (TTM)—

Revenue (annual)0

Net income (annual)-51M

Social

What share of all stock conversation is about SGMT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 24

Goldman Sachs initiated a sell rating on Sagimet Biosciences Inc. (SGMT) with a target price of $7, citing concerns that the company's Phase 3 results may not translate to the U.S. trial, particularly with more adolescents enrolled.
Analyst Andrea Newkirk is being criticized for her bearish view on SGMT, with some accusing her of having a poor track record and using scientifically weak arguments to support her claims.
Other analysts have issued more positive targets for SGMT, with recent estimates ranging from $18 to $31, and some pointing out that Newkirk's concerns are not new clinical data, but rather a reiteration of existing risks.

Generated by AI

Sentiment

Of the messages about SGMT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	20.51% -79.49	47.62% -52.38	84.57% +0.41
Bearish	—	79.49% +79.49	52.38% +52.38	15.43% -0.41

Bullish· Apr 27

$SGMT has significant potential for growth, with a market cap that could reach $750M to $1.5B in the long term, driven by a strong pipeline and potential blockbuster products.
The recent $175M offering has been seen as a positive validation of the company's strategic update, with institutional investors showing confidence in the company's move to prioritize the acne indication.
$SGMT's shares are poised for further gains, with a potential buyout price of $30 and a growing number of investors betting on the stock's upward momentum.

Bearish· Apr 27

The company's recent funding of $175M may not be enough to support its clinical trials, with the need for more money potentially causing a downturn.
The stock is overbought and has shown signs of exhaustion on the chart, with a noted RSI divergence that may lead to a price correction.
The company's recent price surge may be unsustainable, with some investors expecting a crash back down to $6 as the stock is being propped up for a short-term gain.

Generated by AI

Topics

Of the messages about SGMT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	5.56%	7.41%	44.62%
Technical Analysis	—	0%	18.52%	18.89%
Analysts	—	72.22%	59.26%	19.74%
Earnings	—	0%	0%	0.54%
Controversies	—	22.22%	14.81%	1.08%
Macro	—	0%	0%	15.13%

Announcements· Apr 27

Sagimet Biosciences has priced a $175M underwritten offering of Series A common stock at $6.00 per share, with strong institutional participation.
The proceeds from the offering are expected to fund Phase 3 denifanstat trial in acne and broader pipeline expansion, securing the company's cash runway through 2028.
The company plans to initiate a Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the US in H2 2026.

Technical Analysis· Jan 22

$SGMT's price action is expected to be influenced by its VWAP (Volume-Weighted Average Price) breaking and basing.
Technical analysts are targeting $SGMT at 18.50-75 and 20+ possibly 23-25, with support at 10.75-80 and 10-10.25.
$SGMT's hourly RSI is expected to hit the 30s for the next leg up, with some analysts considering it a possible swing entry but also noting it as a risky trade.

Generated by AI

Community

Of the messages about SGMT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	72.95%	66.29%	54.25%
Newcomers	0%	27.05%	33.71%	45.75%

Sep 24

Goldman Sachs has initiated a sell rating for Sagimet Biosciences with a $7.00 price target, citing growth and commercialization risks.
The company's management has been accused of not addressing claims made by Goldman, and the downgrade has resulted in a significant loss for some investors.
There is a possibility that Goldman may be able to "pull an undo" on the downgrade, and some users are speculating about this possibility.

Generated by AI

On August 11, Sagimet Biosciences Inc. (NASDAQ:SGMT) reported financial results for the quarter ended June 30, 2026. Research and development expense rose to $11.5 million from $7.2 million a year earlier as the company prepared for its Phase 3 trial, while general and administrative expense declined slightly to $4.3 million. Net loss widened to $14.0 […]

2d agoYahoo Finance

United Therapeutics, Sagimet drop as Goldman issues Sell (UTHR)

United Therapeutics (UTHR) stock and Sagimet Biosciences (SGMT) stock slip as Goldman Sachs issued Sell ratings on the companies. Read more here.

5d agoSeeking Alpha

Sagimet Biosciences at Cantor conference: acne drug push gains traction

20d agoInvesting.com

Barclays upgrades Sagimet stock rating on acne drug potential

21d agoInvesting.com

Also Discussed

Investors talking about SGMT also mention

#	Name	Attention
1	Aligos Therapeutics, Inc.ALGS	0%new
2	ETNB - 89bio, Inc.	——
3	Madrigal Pharmaceuticals Inc.MDGL	0%-0.02
4	Oric Pharmaceuticals, Inc.ORIC	0%0
5	Ironwood Pharmaceuticals, Inc. Class A Common StockIRWD	0%new
6	Prime Medicine, Inc.PRME	0%-0.01
7	Tango Therapeutics Inc.TNGX	0%new
8	SLRN - Acelyrin, Inc.	——
9	Biomea Fusion Inc.BMEA	0.01%-0.01
10	TERN - Terns Pharmaceuticals, Inc.	——

Sagimet Biosciences Inc. Series A Common Stock

Healthcare
Biotechnology

Sagimet Biosciences Inc. Series A Common Stock represents an equity interest in Sagimet Biosciences, a clinical-stage biopharmaceutical company focused on developing novel therapeutics for metabolic and fibrotic diseases. The company’s current programs center on fatty acid synthase (FASN) inhibitors and other drug candidates designed to address dysfunctional metabolic pathways and tissue fibrosis. Its lead assets include oral therapies under development for conditions such as metabolic dysfunction-associated steatohepatitis and related disorders, along with additional research programs in dermatology and oncology. Sagimet operates as a single business segment devoted to drug discovery, clinical development, and eventual commercialization of targeted therapies. The stock is used by investors to gain exposure to a specialty biotechnology company centered on in-house discovered, mechanism-based treatments for diseases with limited therapeutic options.

Website

Location

155 Bovet Road

San Mateo, CA, 94402

United States

Social

What share of all stock conversation is about SGMT?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Attention	0% 0	0% +0	0% +0	0% 0

Sep 24

Goldman Sachs initiated a sell rating on Sagimet Biosciences Inc. (SGMT) with a target price of $7, citing concerns that the company's Phase 3 results may not translate to the U.S. trial, particularly with more adolescents enrolled.
Analyst Andrea Newkirk is being criticized for her bearish view on SGMT, with some accusing her of having a poor track record and using scientifically weak arguments to support her claims.
Other analysts have issued more positive targets for SGMT, with recent estimates ranging from $18 to $31, and some pointing out that Newkirk's concerns are not new clinical data, but rather a reiteration of existing risks.

Generated by AI

Sentiment

Of the messages about SGMT that take a side, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Bullish	—	20.51% -79.49	47.62% -52.38	84.57% +0.41
Bearish	—	79.49% +79.49	52.38% +52.38	15.43% -0.41

Bullish· Apr 27

$SGMT has significant potential for growth, with a market cap that could reach $750M to $1.5B in the long term, driven by a strong pipeline and potential blockbuster products.
The recent $175M offering has been seen as a positive validation of the company's strategic update, with institutional investors showing confidence in the company's move to prioritize the acne indication.
$SGMT's shares are poised for further gains, with a potential buyout price of $30 and a growing number of investors betting on the stock's upward momentum.

Bearish· Apr 27

The company's recent funding of $175M may not be enough to support its clinical trials, with the need for more money potentially causing a downturn.
The stock is overbought and has shown signs of exhaustion on the chart, with a noted RSI divergence that may lead to a price correction.
The company's recent price surge may be unsustainable, with some investors expecting a crash back down to $6 as the stock is being propped up for a short-term gain.

Generated by AI

Topics

Of the messages about SGMT that carry a topic, what share is each?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y
Announcements	—	5.56%	7.41%	44.62%
Technical Analysis	—	0%	18.52%	18.89%
Analysts	—	72.22%	59.26%	19.74%
Earnings	—	0%	0%	0.54%
Controversies	—	22.22%	14.81%	1.08%
Macro	—	0%	0%	15.13%

Announcements· Apr 27

Sagimet Biosciences has priced a $175M underwritten offering of Series A common stock at $6.00 per share, with strong institutional participation.
The proceeds from the offering are expected to fund Phase 3 denifanstat trial in acne and broader pipeline expansion, securing the company's cash runway through 2028.
The company plans to initiate a Phase 3 clinical trial of denifanstat in moderate to severe acne patients in the US in H2 2026.

Technical Analysis· Jan 22

$SGMT's price action is expected to be influenced by its VWAP (Volume-Weighted Average Price) breaking and basing.
Technical analysts are targeting $SGMT at 18.50-75 and 20+ possibly 23-25, with support at 10.75-80 and 10-10.25.
$SGMT's hourly RSI is expected to hit the 30s for the next leg up, with some analysts considering it a possible swing entry but also noting it as a risky trade.

Generated by AI

Community

Of the messages about SGMT, what share comes from each group?

	1 Day1D	1 Week1W	1 Month1M	1 Year1Y	50-Day MAclick to plot	200-Day MAclick to plot
Regulars	100%	72.95%	66.29%	54.25%
Newcomers	0%	27.05%	33.71%	45.75%

Sep 24

Goldman Sachs has initiated a sell rating for Sagimet Biosciences with a $7.00 price target, citing growth and commercialization risks.
The company's management has been accused of not addressing claims made by Goldman, and the downgrade has resulted in a significant loss for some investors.
There is a possibility that Goldman may be able to "pull an undo" on the downgrade, and some users are speculating about this possibility.

Generated by AI

Sagimet Biosciences

Social

Sep 24

Sentiment

Bullish· Apr 27

Bearish· Apr 27

Topics

Announcements· Apr 27

Technical Analysis· Jan 22

Community

Sep 24

News

H.C. Wainwright reiterates Sagimet stock rating on EADV data

Sagimet to host event on denifanstat acne trial data Wednesday

Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts

United Therapeutics, Sagimet drop as Goldman issues Sell (UTHR)

Sagimet Biosciences at Cantor conference: acne drug push gains traction

Barclays upgrades Sagimet stock rating on acne drug potential

Also Discussed

Sagimet Biosciences Inc. Series A Common Stock

Company Information

Location

News

H.C. Wainwright reiterates Sagimet stock rating on EADV data

Sagimet to host event on denifanstat acne trial data Wednesday

Sagimet Biosciences (SGMT): Phase 3 Trial, FDA Path and Cash Runway Set Up Key Catalysts

United Therapeutics, Sagimet drop as Goldman issues Sell (UTHR)

Sagimet Biosciences at Cantor conference: acne drug push gains traction

Barclays upgrades Sagimet stock rating on acne drug potential

Also Discussed

Social

Sep 24

Sentiment

Bullish· Apr 27

Bearish· Apr 27

Topics

Announcements· Apr 27

Technical Analysis· Jan 22

Community

Sep 24